Payment overview · 2025
General Payments
$447.23
19 reported records · 13 companies
Healthcare provider profile · identity verified
Pomilla Kumar, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BETTENDORF, IA · NPI 1568431880
Verified facts
What the public records show
CMS Open Payments records show Pomilla Kumar, M.D. received $447.23 in general payments during 2025 across 19 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 567 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $63.02 | 14.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $55.34 | 12.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.42 | 11.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.53 | 10.4% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.20 | 9.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.46 | 7.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.87 | 6.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.27 | 5.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.09 | 5.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.70 | 5.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.85 | 4.9% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.19 | 4.7% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.29 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $447.23 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $105.76 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $63.02 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $41.20 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.46 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.87 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.18 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | SANOFI PASTEUR INC. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
90 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
567 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1119 | 128 |
| Furosemide | Furosemide | 783 | 71 |
| Gabapentin | Gabapentin | 769 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 632 | 78 |
| Potassium Chloride | Potassium Chloride | 573 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 569 | 65 |
| Eliquis | Apixaban | 567 | 54 |
| Lisinopril | Lisinopril | 539 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 519 | 69 |
| Metformin Hcl | Metformin Hcl | 435 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 383 | 40 |
| Trazodone Hcl | Trazodone Hcl | 348 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 344 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 315 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 310 | 47 |
| Sertraline Hcl | Sertraline Hcl | 309 | 41 |
| Montelukast Sodium | Montelukast Sodium | 275 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 274 | 34 |
| Baclofen | Baclofen | 270 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 268 | 28 |
| Buspirone Hcl | Buspirone Hcl | 263 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 240 | 32 |
| Spironolactone | Spironolactone | 236 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 225 | 29 |
| Carvedilol | Carvedilol | 218 | 23 |
| Tramadol Hcl | Tramadol Hcl | 216 | 32 |
| Levetiracetam | Levetiracetam | 215 | 17 |
| Simvastatin | Simvastatin | 210 | 34 |
| Mirtazapine | Mirtazapine | 206 | 24 |
| Allopurinol | Allopurinol | 194 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 170 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 169 | 13 |
| Donepezil Hcl | Donepezil Hcl | 168 | 16 |
| Meloxicam | Meloxicam | 165 | 25 |
| Losartan Potassium | Losartan Potassium | 161 | 33 |
| Omeprazole | Omeprazole | 157 | 32 |
| Finasteride | Finasteride | 147 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 138 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 23 |
| Metolazone | Metolazone | 136 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 132 | 15 |
| Metformin Hcl Er | Metformin Hcl | 130 | 16 |
| Midodrine Hcl | Midodrine Hcl | 130 | 21 |
| Bupropion Xl | Bupropion Hcl | 122 | 22 |
| Jardiance | Empagliflozin | 122 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 115 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 113 | suppressed |
| Sucralfate | Sucralfate | 112 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 106 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 103 | suppressed |
| Memantine Hcl | Memantine Hcl | 103 | suppressed |
| Torsemide | Torsemide | 103 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 102 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 49 |
| Prednisone | Prednisone | 98 | 47 |
| Pregabalin | Pregabalin | 91 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 90 | suppressed |
| Trulicity | Dulaglutide | 90 | suppressed |
| Xarelto | Rivaroxaban | 90 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 88 | suppressed |
| Clonazepam | Clonazepam | 84 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 78 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 11 |
| Januvia | Sitagliptin Phosphate | 75 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 74 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 72 | 34 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 72 | suppressed |
| Ozempic | Semaglutide | 71 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 70 | 27 |
| Atenolol | Atenolol | 69 | 15 |
| Nifedipine Er | Nifedipine | 69 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | suppressed |
| Alprazolam | Alprazolam | 67 | 17 |
| Insulin Lispro | Insulin Lispro | 67 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 64 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | suppressed |
| Lamotrigine | Lamotrigine | 63 | suppressed |
| Latanoprost | Latanoprost | 62 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 61 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 60 | suppressed |
| Glimepiride | Glimepiride | 56 | suppressed |
| Famotidine | Famotidine | 55 | 14 |
| Clonidine Hcl | Clonidine Hcl | 52 | suppressed |
| Lorazepam | Lorazepam | 51 | 22 |
| Sevelamer Carbonate | Sevelamer Carbonate | 51 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 50 | 25 |
| Propranolol Hcl Er | Propranolol Hcl | 49 | suppressed |
| Sotalol | Sotalol Hcl | 49 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 48 | suppressed |
| Ezetimibe | Ezetimibe | 46 | suppressed |
| Azithromycin | Azithromycin | 43 | 30 |
| Haloperidol | Haloperidol | 43 | suppressed |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 40 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Pentoxifylline | Pentoxifylline | 39 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 38 | 19 |
| Prazosin Hcl | Prazosin Hcl | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Risperidone | Risperidone | 37 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 17 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 14 |
| Movantik | Naloxegol Oxalate | 34 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 16 |
| Olanzapine | Olanzapine | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 18 |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 29 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 29 | suppressed |
| Roflumilast | Roflumilast | 29 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Lacosamide | Lacosamide | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Nadolol | Nadolol | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Ramelteon | Ramelteon | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Nabumetone | Nabumetone | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 11 |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Humalog | Insulin Lispro | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | 14 |
| Verapamil Hcl | Verapamil Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 12 |
| Dulera | Mometasone/Formoterol | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Levemir | Insulin Detemir | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | 13 |
| Nyamyc | Nystatin | 17 | 12 |
| Sulfasalazine | Sulfasalazine | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Rytary | Carbidopa/Levodopa | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Scopolamine | Scopolamine | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $447.23 · 19 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, AUSTEDO XR, BEYFORTUS, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, INGREZZA, Jornay PM, KISUNLA, Ozempic, PAXLOVID, PREVNAR 20, Qelbree, REXULTI, VAXELIS, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error